| Name | Title | Contact Details |
|---|
Complementary Healthcare Plans is a Hopkins, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Blueprint Medicines is developing a new generation of highly selective and potent kinase therapies to dramatically improve the lives of patients with genomically defined diseases. Our approach is rooted in a deep understanding of the genetic blueprint of cancer and other diseases driven by the abnormal activation of kinases. Our ability to identify novel drivers of disease, coupled with our proprietary library of novel and diverse chemical compounds, uniquely enables us to craft kinase therapies against new and difficult-to-drug targets. We are boldly advancing a deep pipeline of highly targeted therapies against previously unaddressed drivers of disease. By focusing on genomically defined subsets of patients, we believe we can identify the people most likely to respond to our therapies, resulting in a more efficient clinical development path with a greater likelihood of success and better outcomes for patients. We see a substantial opportunity in kinase drug discovery and development to deliver breakthrough medicines that allow patients to live longer with better quality of life and prevent recurrences of disease. Kinases are involved in many hallmarks of tumor biology and are proven cancer drug targets. Currently approved drugs focus on less than 5 percent of known kinases, and the function of most kinases is unknown. Led by a team of industry innovators with a track record of bringing life-changing drugs to market, we believe Blueprint Medicines has the experience and expertise to deliver on the tremendous untapped potential of kinase therapies to improve patients’ lives. We don’t think in small steps. We think in giant leaps. We are driven by the pursuit of new ideas, new innovations, and new ways of thinking.
The MBX Difference: Relationship Based Partnerships Our bottom line in your bottom line. We don`t simply chase the low-hanging fruit. Put simply, our outsourced revenue cycle management will collect more dollars, improve your cash flow, support your physicians and delight your patients. MBX is a growing organization specializing in radiology billing. With MBX, from the start of our relationship to go live, you are in safe hands. Our experienced leadership team, who between them possess over seven decades of working with some of the nation’s leading radiology group practices, has implemented over 300 outsourced revenue cycle management systems. We process millions of procedures per year for practices from coast to coast, as diverse as three provider interventional radiologists in Oregon to a 100+ provider practice in North Carolina. MBX delivers consistent and exceptional revenue cycle management. We bill and collect every possible dollar by capitalizing on operational expertise that is second to none. Our exceptional rate of claims accepted the first time, along with our strong denials management process, ensures that claims are processed quickly and denials handled efficiently and effectively. Our end-to-end service extends from the point at which we receive the physician’s dictated report all the way through to the patient’s account at zero balance – we worry about the billing, you lower your operational overheads.
Bionor Pharma is a leading biotechnology company advancing the first therapeutic vaccine towards a functional cure for HIV. The company`s focus is the research and development of peptide-based vaccines against viral diseases, primarily HIV. Bionor Pharma`s most advanced product candidate is Vacc-4x, which is also the most advanced therapeutic vaccine in the HIV space and has demonstrated a reduction of viral load in a large, randomized, controlled Phase II trial, as well as safety and tolerability. Pharma`s current clinical focus is to explore whether Vacc-4x, used with other medicines as a combination therapy, can reduce the viral load even further, and the company, through collaboration with Celgene, is investigating Vacc-4x and the HDAC inhibitor romidepsin in the REDUC study. In May 2015, Bionor Pharma announced promising results from an interim analysis of Part B of the REDUC study. In the study, Vacc-4x and romidepsin are explored as a possible treatment regimen to reduce the persistent latent viral reservoir in HIV infected patients on anti-retroviral treatment. Results are expected in the second half of 2015. Bionor Pharma is headquartered in Oslo, Norway, with offices in Copenhagen and New York.
Health Access Washoe County is a Reno, NV-based company in the Healthcare, Pharmaceuticals, and Biotech sector.